Skip to main content
Premium Trial:

Request an Annual Quote

NimbleGen, LICR, Iceland Genomics Get $1.7M NCI Grant to Map Cancer Pathways

NEW YORK, Oct. 12 (GenomeWeb News) - The National Cancer Institute has awarded NimbleGen, the Ludwig Institute for Cancer Research, and Iceland Genomics a $1.7 million, 4-year grant to map regulatory pathways in cancer, NimbleGen said today.

Specifically, NimbleGen and the University of San Diego branch of the LICR will co-develop next generation chromatin immunoprecipitation (ChIP)-on-chip methodologies to map transcription factor binding sites throughout the human genome. Iceland Genomics will provide samples from its clinical cancer database to be screened for TF binding using the new methodology.

It is not the first time the three have worked together. NimbleGen and LICR worked together on ChIP-on-chip technologies within the ENCODE consortium, while Iceland Genomics helped NimbleGen open its Reykjavik-based subsidiary in that country in 2002.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more